STAT3 and hepatocellular carcinoma: We observed no significant connection between STAT3 rs1053004 polymorphism and CHB-related HCC risk (C vs. T: OR = 1.04, 95% CI: 0.93–1.15, PA=0.52; CC + CT vs. TT: OR = 1.03, 95% CI: 0.89–1.19, PA=0.71; CC vs. CT + TT: OR = 0.98, 95% CI: 0.58–1.67, PA=0.95).